Should selective Cox-2 inhibitors be used more?

M. Nandave, S. Ojha, D. Arya

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


The discovery of inducible cyclooxygenase-2 enzyme led to the development of a new generation of nonsteroidal antiinflammatory drugs, most commonly known as coxibs. Within a short span of time, coxibs became the most widely prescribed drugs (with annual sale of more than $5 billion in the US) due to their gastroprotective effect. But immediate and voluntarily withdrawal of rofecoxib due to excessive cardiac morbidity reported with its chronic use has raised questions about their superior overall safety profile. This review summarizes the evidence regarding the use of coxibs and associated cardiovascular risk; mechanisms underlying the coxibs-mediated cardiovascular risk and other thrombotic events, evidence for a differential effect on cardiotoxicity among coxibs, and recent trends in the antiinflammatory therapy.

Original languageEnglish
Pages (from-to)281-285
Number of pages5
JournalIndian Journal of Pharmaceutical Sciences
Issue number3
Publication statusPublished - Feb 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Should selective Cox-2 inhibitors be used more?'. Together they form a unique fingerprint.

Cite this